Stanniocalcin-2 Regulates Linear Growth via Growth Hormone/Insulin-like Growth Factor-1 Axis in Idiopathic Short Stature
Amjed Hussein Jawad, Seenaa Bader Mohamed, Alaa Jafear MahrathBackground:
Idiopathic short stature (ISS) is characterized by a height below the mean for age, sex, and population, without identifiable systemic, endocrine, nutritional, or chromosomal abnormalities. Dysregulation of the growth hormone/insulin-like growth factor-1 (IGF-1) axis, particularly IGF-1 bioavailability, is a suspected contributor. Stanniocalcin-2 (STC2) inhibits pregnancy-associated plasma protein-A2, a protease that releases IGF-1 from its binding proteins. To investigate the association between circulating STC2 level, free IGF-1 bioavailability, and linear growth in children with ISS.
Methods:
This case–control study included 88 participants (45 children with ISS, 43 controls) aged 4–18 years. Serum STC2, total IGF-1, free IGF-1, and insulin-like growth factor-binding proteins (IGFBP)-3 levels were measured by the ELISA.
Results:
Children with ISS exhibited significantly lower free IGF-1 (213 vs. 291 pg/mL,
Conclusion:
Impaired growth in ISS was more closely associated with reduced IGF-1 bioavailability than with deficient production. Elevated STC2 levels, particularly in older children, contribute to a decrease in free IGF-1 levels.